scispace - formally typeset
F

Fazlul H. Sarkar

Researcher at Wayne State University

Publications -  626
Citations -  48133

Fazlul H. Sarkar is an academic researcher from Wayne State University. The author has contributed to research in topics: Cancer & Pancreatic cancer. The author has an hindex of 114, co-authored 625 publications receiving 44744 citations.

Papers
More filters
Journal ArticleDOI

Molecular alterations associated with improved survival in pancreatic cancer patients treated with radiation or chemotherapy.

TL;DR: Findings suggest promising opportunities for gene therapies designed to enhance p21 expression or restore wild-type K-ras or p53 function in Pancreas cancer patients whose tumors express p21 show significant survival advantages when treated with chemotherapy or radiation therapy.
Journal ArticleDOI

B-DIM impairs radiation-induced survival pathways independently of androgen receptor expression and augments radiation efficacy in prostate cancer

TL;DR: It is demonstrated that B-DIM augments radiation-induced cell killing and tumor growth inhibition and impairs critical survival signaling pathways activated by radiation, leading to enhanced cell killing.
Journal ArticleDOI

Anticancer phytochemical analogs 37: synthesis, characterization, molecular docking and cytotoxicity of novel plumbagin hydrazones against breast cancer cells.

TL;DR: Cytotoxicity of novel plumbagin hydrazones against estrogen and progesterone receptor positive (ER+/PR+) MCF-7 and triple negative MDA-MB-231 breast cancer cell lines is examined and these compounds can provide a starting point for the development of novel drug molecules against triple negative breast cancers.
Journal ArticleDOI

PAR-4 as a possible new target for pancreatic cancer therapy

TL;DR: This review provides comprehensive knowledge of the significance of Par-4 and its association with kras status in PC, along with the crosstalk with crucial resistance and survival molecules NF-κB and Bcl-2 that ultimately are responsible for the overall poor outcome of different therapeutic approaches in this disease.
Patent

Antibodies to a novel EGF-receptor related protein (ERRP)

TL;DR: In this article, the authors used ERRP (EGF-Receptor Related Protein) specific antibodies that could be used to study the functional properties of ERRP and as a diagnostic and prognostic tool for malignancies.